Drug Dealin' Ep. 1: Do Pharma companies avoid cures?

In this episode, we unpack, examine, and debunk the public perception that drug companies intentionally do not pursue curative therapies, because it is financially less beneficial to them. We speak from our own experience working on curative therapies in Oncology and HCV, discuss how difficult it is to develop cures, the implications of curing a disease for drug companies, and how the industry can do a better job fostering trust with patients.

Have feedback for us? Feel free to leave a comment or send us an email at DrugDealinPod@gmail.com

Summary

This conversation delves into the complexities surrounding the development of cures in the biotech and pharmaceutical industries. It explores the financial incentives that may deter companies from pursuing cures, the public's perception of the industry, and the role of government in healthcare. The discussion highlights the challenges faced in developing cures, using the case study of Hepatitis C (HCV) as a focal point. It emphasizes the importance of lifestyle choices in health outcomes, innovative payment models for curative treatments, and the necessity of maintaining a strong connection between the industry and patients. Education and awareness are underscored as vital components in fostering understanding and trust in the healthcare system.

Takeaways

• Biotech and pharma companies often face skepticism regarding their motives for not pursuing cures.

• Cures can be more expensive due to the extensive research and development required.

• Public perception of the industry is influenced by high drug prices and trust issues.

• Government intervention can play a crucial role in making cures accessible.

• Lifestyle choices significantly impact health outcomes and disease prevalence.

• Innovative payment models could help align financial incentives with public health goals.

• The HCV case study illustrates the complexities of pricing and access to curative treatments.

• Education and awareness are essential for improving public understanding of cures.

• Maintaining a connection with patients can enhance trust in the healthcare system.

• The future of healthcare innovation relies on competition and collaboration among industry players.